Edwards Lifesciences Corporation $EW Shares Sold by Swiss National Bank

Swiss National Bank trimmed its stake in Edwards Lifesciences Corporation (NYSE:EW) by 4.6% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 1,691,000 shares of the medical research company’s stock after selling 82,100 shares during the quarter. Swiss National Bank owned approximately 0.29% of Edwards Lifesciences worth $131,509,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in EW. Brighton Jones LLC purchased a new position in Edwards Lifesciences in the 4th quarter valued at about $266,000. Atlantic Union Bankshares Corp purchased a new position in shares of Edwards Lifesciences during the second quarter valued at approximately $40,000. Savant Capital LLC boosted its position in Edwards Lifesciences by 16.4% during the second quarter. Savant Capital LLC now owns 25,842 shares of the medical research company’s stock worth $2,021,000 after acquiring an additional 3,637 shares during the last quarter. Parkside Financial Bank & Trust raised its holdings in Edwards Lifesciences by 9.8% in the 2nd quarter. Parkside Financial Bank & Trust now owns 1,455 shares of the medical research company’s stock valued at $114,000 after acquiring an additional 130 shares during the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. purchased a new position in shares of Edwards Lifesciences during the 2nd quarter worth $3,800,000. Institutional investors and hedge funds own 79.46% of the company’s stock.

Insider Activity at Edwards Lifesciences

In related news, VP Donald E. Bobo, Jr. sold 24,000 shares of Edwards Lifesciences stock in a transaction dated Wednesday, February 25th. The stock was sold at an average price of $83.84, for a total value of $2,012,160.00. Following the completion of the transaction, the vice president directly owned 21,266 shares in the company, valued at approximately $1,782,941.44. This trade represents a 53.02% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, VP Daniel J. Lippis sold 1,019 shares of the business’s stock in a transaction dated Friday, January 9th. The shares were sold at an average price of $85.70, for a total value of $87,328.30. Following the completion of the sale, the vice president directly owned 22,002 shares of the company’s stock, valued at approximately $1,885,571.40. This represents a 4.43% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 60,104 shares of company stock valued at $5,084,637. Company insiders own 0.34% of the company’s stock.

Edwards Lifesciences Stock Up 1.8%

Shares of NYSE:EW opened at $85.76 on Wednesday. The company has a market capitalization of $49.81 billion, a price-to-earnings ratio of 46.86, a price-to-earnings-growth ratio of 2.20 and a beta of 0.93. The company has a 50 day moving average of $82.50 and a two-hundred day moving average of $81.52. Edwards Lifesciences Corporation has a 52-week low of $65.94 and a 52-week high of $87.89. The company has a quick ratio of 3.09, a current ratio of 3.72 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW) last announced its earnings results on Tuesday, February 10th. The medical research company reported $0.58 earnings per share for the quarter, missing the consensus estimate of $0.62 by ($0.04). Edwards Lifesciences had a net margin of 17.69% and a return on equity of 14.50%. The firm had revenue of $1.57 billion during the quarter, compared to analysts’ expectations of $1.54 billion. During the same quarter last year, the company posted $0.59 earnings per share. Edwards Lifesciences’s revenue for the quarter was up 13.3% compared to the same quarter last year. Edwards Lifesciences has set its Q1 2026 guidance at 0.700-0.760 EPS. As a group, analysts forecast that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current fiscal year.

Analyst Ratings Changes

EW has been the subject of a number of recent analyst reports. The Goldman Sachs Group reaffirmed a “buy” rating and issued a $95.00 price objective (down from $108.00) on shares of Edwards Lifesciences in a research report on Wednesday, February 11th. Wells Fargo & Company raised their price target on Edwards Lifesciences from $96.00 to $100.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 11th. UBS Group restated a “neutral” rating and issued a $94.00 price target on shares of Edwards Lifesciences in a report on Wednesday, February 4th. Royal Bank Of Canada boosted their target price on shares of Edwards Lifesciences from $95.00 to $100.00 and gave the company an “outperform” rating in a report on Friday, December 5th. Finally, BTIG Research restated a “buy” rating and set a $103.00 price objective on shares of Edwards Lifesciences in a report on Wednesday, February 11th. Three investment analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and nine have issued a Hold rating to the company. Based on data from MarketBeat.com, Edwards Lifesciences currently has a consensus rating of “Moderate Buy” and an average price target of $96.14.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.